Liposomal Amphotericin B

@article{Moen2012LiposomalAB,
  title={Liposomal Amphotericin B},
  author={Marit D. Moen and Katherine A. Lyseng-Williamson and Lesley J. Scott},
  journal={Drugs},
  year={2012},
  volume={69},
  pages={361-392}
}
SummaryAbstractLiposomal amphotericin B (AmBisome®) is a lipid-associated formulation of the broad-spectrum polyene antifungal agent amphotericin B. It is active against clinically relevant yeasts and moulds, including Candida spp., Aspergillus spp. and filamentous moulds such as Zygomycetes, and is approved for the treatment of invasive fungal infections in many countries worldwide. It was developed to improve the tolerability profile of amphotericin B deoxycholate, which was for many decades… 
Deoxycholate Amphotericin B and Nephrotoxicity in the Pediatric Setting
Since the introduction of amphotericin B as an antifungal agent, the morbidity and mortality of pediatric patients with mycotic infections have increased, primarily because of the increased
Development and Evaluation of Antifungal in vivo of Liposomal Amphotericin B
TLDR
Results have shown that liposomal amphotericin B prepared by both methods have strong effect to prolong the survival in the infected mice and significantly reduced the Colony Forming Units (CFU) in target organ with similar effect of AmBisome.
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
TLDR
The few comparative clinical trials that have been completed with the lipid-associated formulations have not demonstrated important clinical differences among these agents and amphotericin B for efficacy, although there are significant safety benefits of the lipid products.
Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
TLDR
While pentavalent antimony salts were found to increase biochemical and hematological findings, liposomal amphotericin B was responsible for rapid recovery in fever and shorter hospital stay, and shows the advantages of both medications independent of their costs.
Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged
TLDR
It is suggested that low-dose L-AmB may be an effective option as empirical antifungal therapy for high-risk patients with febrile neutropenia.
Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B.
TLDR
After the intravenous administration of LAmB, AmB CSF levels were low, confirming published animal data, and higher levels in brain tissue, which would be necessary for the successful treatment of CNS infections, might be possible.
Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?
TLDR
Three different lipid formulations of amphotericin B show significantly different structural, physical, chemical, pharmacokinetic, pharmacodynamic and toxicological characteristics, and therapeutic non-equivalence of the three lipid formulations is supported.
Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia
TLDR
This study suggests that low-dose L-AmB may be an effective option as empirical antifungal therapy for high-risk patients with febrile neutropenia.
Liposomal amphotericin B as a treatment for human leishmaniasis
TLDR
A review of clinical studies on LAMB for VL and other forms of leishmaniasis is provided, finding it to be highly efficacious and safe in over 8000 VL patients treated by MÉdecins Sans Frontières in South Asia, and its use was feasible even at primary healthcare level.
Comparison between liposomal formulations of amphotericin B.
TLDR
Studies have shown that a comparison of liposomal amphotericin B products with different or the same chemical compositions will vary in size, and have significantly dissimilar in vitro and in vivo toxicities along with reduced efficacy, underscore the importance of establishing appropriate bioequivalence testing for liposome products to ensure uniformity of their therapeutic index.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 114 REFERENCES
Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
TLDR
Liposomal amphotericin B is an effective treatment for visceral leishmaniasis in immunocompetent adults and children, including those with severe or drug-resistant disease and the drug also produces good response rates in Immunocompromised patients; however, relapse rates in these patients are high.
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
TLDR
A randomized, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphoteric in B as empirical antifungal therapy for patients with persistent fever and neutropenia.
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
TLDR
Caspofungin is as effective as and generally better tolerated than liposomal amphotericin B when given as empirical antifungal therapy in patients with persistent fever and neutropenia.
Overview of the lipid formulations of amphotericin B.
  • B. Dupont
  • Medicine
    The Journal of antimicrobial chemotherapy
  • 2002
TLDR
In some patients with life-threatening mycosis who failed treatment with, or were intolerant to, amphotericin B, the lipid formulations were effective; further studies with comparable selected high-risk patients are warranted to clarify the usefulness and the indications of each of the formulations.
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
TLDR
Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.
Caspofungin: a review of its use in the treatment of fungal infections.
TLDR
Caspofungin is a viable alternative to amphotericin B deoxycholate, liposomal amph esotericin B or fluconazole in the appropriate indications and was effective as salvage therapy in patients with invasive aspergillosis who were refractory to or intolerant of standard therapy.
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
TLDR
Liposomal amphotericin B is as effective as conventional amphoteric in B for empirical antifungal therapy in patients with fever and neutropenia, and it is associated with fewer breakthrough fungal infections, less infusion-related toxicity, and less nephrotoxicity.
Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS
TLDR
Although expensive, liposomal amphotericin B is better than regular amphoteric in B for treating severe disseminated histoplasmosis in patients with AIDS and AIDS.
Voriconazole versus amphotericin B in cancer patients with neutropenia.
TLDR
Liposomal amphotericin B is significantly more effective than voriconazole for empirical therapy of neutropenic cancer patients and should be preferred, and for treatment of aspergillosis, there are no trials that have compared vorIconazole with amphoteric in B given under optimal conditions.
Amphotericin B lipid preparations: what are the differences?
  • J. Adler-Moore, R. Proffitt
  • Medicine
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2008
TLDR
With the recent introduction of new antifungal drugs to treat the increasing numbers of infected patients, the amphotericin B lipid formulations are now being studied to evaluate their potential in combination drug regimens.
...
1
2
3
4
5
...